Compare Stocks

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGXX Bright Green	$0.21 -4.5%	$0.24	$0.15 ▼ $1.81	$40.37M	0.72	1.76 million shs	365,834 shs
HEXO HEXO	$0.71 +2.5%	$0.87	$0.66 ▼ $3.84	$31.24M	1.35	880,508 shs	305,500 shs
MDWD MediWound	$15.77 -7.2%	$14.94	$7.10 ▼ $18.75	$149.69M	0.93	69,808 shs	106,833 shs
MNMD Mind Medicine (MindMed)	$8.68 -2.6%	$7.98	$2.41 ▼ $12.22	$609.94M	2.81	1.95 million shs	1.52 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGXX Bright Green	+2.11%	-7.25%	-21.43%	-17.56%	-85.26%
HEXO HEXO	0.00%	0.00%	0.00%	0.00%	-40.83%
MDWD MediWound	-2.58%	+7.19%	+8.01%	+30.69%	+36.80%
MNMD Mind Medicine (MindMed)	-6.51%	-13.07%	-8.99%	+148.19%	+133.86%

Tiny Biotech Stock Wins $75 Billion Patent (Ad)

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGXX Bright Green	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HEXO HEXO	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	1.5638 of 5 stars	3.5	3.0	0.0	0.0	1.3	0.8	0.6
MNMD Mind Medicine (MindMed)	1.8538 of 5 stars	3.5	2.0	0.0	0.0	3.1	0.8	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGXX Bright Green	N/A	N/A	N/A	N/A
HEXO HEXO	N/A	N/A	N/A	N/A
MDWD MediWound	3.00	Buy	$32.00	102.92% Upside
MNMD Mind Medicine (MindMed)	3.00	Buy	$25.20	190.32% Upside

Current Analyst Ratings

Latest MNMD, BGXX, HEXO, and MDWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	MNMD Mind Medicine (MindMed)	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/15/2024	MNMD Mind Medicine (MindMed)	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
3/22/2024	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
3/14/2024	MNMD Mind Medicine (MindMed)	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
3/1/2024	MNMD Mind Medicine (MindMed)	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
2/29/2024	MNMD Mind Medicine (MindMed)	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$14.00 ➝ $15.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGXX Bright Green	N/A	N/A	N/A	N/A	$0.07 per share	N/A
HEXO HEXO	$146.20M	0.21	N/A	N/A	$2.44 per share	0.29
MDWD MediWound	$18.69M	8.01	N/A	N/A	$3.43 per share	4.60
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$1.90 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGXX Bright Green	-$27.66M	-$0.08	N/A	∞	N/A	N/A	-73.26%	-39.82%	5/27/2024 (Estimated)
HEXO HEXO	-$845.90M	-$5.21	N/A	N/A	N/A	-235.33%	-74.04%	-32.51%	N/A
MDWD MediWound	-$6.72M	-$0.77	N/A	N/A	N/A	-35.94%	-20.22%	-10.08%	6/4/2024 (Estimated)
MNMD Mind Medicine (MindMed)	-$95.73M	-$2.45	N/A	N/A	N/A	N/A	-89.72%	-65.33%	5/2/2024 (Estimated)

Latest MNMD, BGXX, HEXO, and MDWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	MDWD MediWound	-$0.23	-$0.19	+$0.04	-$0.19	$5.33 million	$5.34 million
2/28/2024	Q4 2023	MNMD Mind Medicine (MindMed)	-$0.48	-$0.59	-$0.11	-$0.59	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGXX Bright Green	N/A	N/A	N/A	N/A	N/A
HEXO HEXO	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGXX Bright Green	N/A	0.03	0.03
HEXO HEXO	0.01	0.41	0.24
MDWD MediWound	N/A	4.59	4.33
MNMD Mind Medicine (MindMed)	0.18	3.22	3.22

Ownership

Institutional Ownership

Company	Institutional Ownership
BGXX Bright Green	7.83%
HEXO HEXO	7.78%
MDWD MediWound	46.83%
MNMD Mind Medicine (MindMed)	27.91%

Insider Ownership

Company	Insider Ownership
BGXX Bright Green	51.38%
HEXO HEXO	4.69%
MDWD MediWound	9.20%
MNMD Mind Medicine (MindMed)	2.11%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BGXX Bright Green	23	190.17 million	89.40 million	Optionable
HEXO HEXO	1,277	44.00 million	41.93 million	Optionable
MDWD MediWound	100	9.49 million	8.62 million	Optionable
MNMD Mind Medicine (MindMed)	57	70.27 million	68.79 million	Optionable

MNMD, BGXX, HEXO, and MDWD Headlines

Source	Headline
	Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked' msn.com - April 19 at 7:58 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 2.9% marketbeat.com - April 18 at 3:41 PM
	Leerink Partnrs Reaffirms Outperform Rating for Mind Medicine (MindMed) (NASDAQ:MNMD) americanbankingnews.com - April 18 at 2:02 AM
	Analysts Set Expectations for Mind Medicine (MindMed) Inc.'s Q1 2024 Earnings (NASDAQ:MNMD) americanbankingnews.com - April 18 at 1:28 AM
	Leerink Partnrs Weighs in on Mind Medicine (MindMed) Inc.'s Q1 2024 Earnings (NASDAQ:MNMD) marketbeat.com - April 17 at 4:48 PM
	Leerink Partnrs Reaffirms "Outperform" Rating for Mind Medicine (MindMed) (NASDAQ:MNMD) marketbeat.com - April 17 at 4:40 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 3.1% marketbeat.com - April 17 at 1:11 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap Up to $9.67 americanbankingnews.com - April 17 at 5:15 AM
	Leerink Partners Initiates Coverage of Mind Medicine (MNMD) with Outperform Recommendation msn.com - April 16 at 10:36 AM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Coverage Initiated by Analysts at SVB Leerink americanbankingnews.com - April 16 at 4:50 AM
	Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Short Interest Up 23.2% in March marketbeat.com - April 15 at 9:35 PM
	SVB Leerink Initiates Coverage on Mind Medicine (MindMed) (NASDAQ:MNMD) marketbeat.com - April 15 at 8:35 AM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 3.2% americanbankingnews.com - April 14 at 3:56 AM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 6.5% marketbeat.com - April 11 at 2:49 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 7.3% marketbeat.com - April 10 at 1:39 PM
	Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of "Buy" from Analysts americanbankingnews.com - April 10 at 2:16 AM
	Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Average Recommendation of "Buy" by Analysts marketbeat.com - April 10 at 2:14 AM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 5.4% marketbeat.com - April 9 at 12:54 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Trading 3.2% Higher marketbeat.com - April 8 at 12:46 PM
	MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why zacks.com - April 8 at 8:01 AM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Trading 1.5% Higher marketbeat.com - April 5 at 1:49 PM
	Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data seekingalpha.com - April 4 at 1:30 PM
	Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap Up to $11.75 marketbeat.com - April 4 at 1:20 PM
	Three Stocks: MindMed, Ulta, and Intel moneymorning.com - April 4 at 3:29 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bright Green

NASDAQ:BGXX

Bright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.

HEXO

NYSE:HEXO

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.

MediWound

NASDAQ:MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Mind Medicine (MindMed)

NASDAQ:MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial